<DOC>
	<DOCNO>NCT01128842</DOCNO>
	<brief_summary>This open-label , phase 1 study ascend single cohort neratinib ( HKI-272 ) combination capecitabine .</brief_summary>
	<brief_title>A Study Of Neratinib ( HKI-272 ) And Capecitabine In Japanese With Solid Tumor</brief_title>
	<detailed_description />
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Male female subject 20 year old Confirmed pathologic diagnosis solid tumor curable currently available therapy , neratinib plus capecitabine reasonable treatment option . At least 1 measurable lesion define Response Evaluation Criteria Solid Tumors ( RECIST ) criterion ( Please note : ascites , pleural pericardial effusion , osteoblastic bone metastasis , carcinomatous lymphangitis lung consider measurable lesion ) . Subjects skin lesion measurable compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) site measurable disease allow . Recovery clinically significant adverse event ( AEs ) relate prior therapy ( exclude alopecia ) . Left ventricular ejection fraction ( LVEF ) within institutional range normal measure multigated acquisition ( MUGA ) echocardiogram ( ECHO ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 ( decline within 2 week sign informed consent form [ ICF ] ) . Screening lab value within follow parameter : Absolute neutrophil count ( ANC ) : 1.5×109/L ( 1500/mm3 ) Platelet count : 100×109/L ( 100,000/mm3 ) Hemoglobin : 9.0 g/dL ( 90 g/L ) Serum creatinine : 01.5×upper limit normal ( ULN ) Total bilirubin : 1.5×ULN ( &lt; 3 ULN Gilbert 's disease ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) : 2.5×ULN ( =5×ULN liver metastasis present ) For woman childbearing potential , negative urine serum pregnancy test result study entry . All subject biologically capable child must agree commit use reliable method birth control duration study 28 day last dose investigational product . A subject biologically capable child use contraceptive sexual partner sterile use contraceptive . Prior treatment anthracyclines cumulative dose doxorubicin &gt; 400 mg/m² , epirubicin &gt; 800 mg/m² , equivalent dose anthracyclines derivative . Major surgery , chemotherapy , radiotherapy , investigational agent , cancer therapy within least 2 week administration first dose investigational product . Bone ONLY site disease . Active central nervous system ( CNS ) metastases , indicate clinical symptom , cerebral edema , and/or progressive growth ( subject history CNS metastases cord compression permit definitively treated anticonvulsant steroid least 4 week cycle 1 day 1 ) . QT ( correct QT ( QTc ) ) interval &gt; 0.47seconds know history QTc prolongation torsades de pointes . Presence clinically significant uncontrolled cardiac disease , include congestive heart failure ( New York Heart Association [ NYHA ] functional classification 02 ) , angina require treatment , myocardial infarction within past 12 month , clinically significant supraventricular arrhythmia ventricular arrhythmia require treatment intervention . Pregnant breastfeed woman . Significant chronic recent acute gastrointestinal disorder diarrhea major symptom ( eg , Crohn 's disease , malabsorption , grade 2 high diarrhea etiology baseline ) . Inability unwillingness swallow tablet ( neratinib capecitabine ) . Subjects active uncontrolled renal insufficiency , medication dose adjustment indicate . Subject know human immunodeficiency virus ( HIV ) seropositive and/or acute chronic hepatitis B infection ( hepatitis B surface antigen [ HBsAg ] positive ) hepatitis C infection ( antiHCV positive ) . Known history hypersensitivity capecitabine component , include 5FU . Any cancer within 5 year prior screen exception contralateral breast carcinoma , adequately treated cervical carcinoma situ , adequately treat basal squamous cell carcinoma skin . Clinically significant ongoing recent infection within 2 week administration first dose investigational product . Evidence significant medical illness abnormal laboratory finding investigator 's judgment substantially increase risk associate subject 's participation completion study , preclude evaluation subject 's response . Examples include , limited , serious active infection , ( ie , require intravenous antibiotic antiviral agent ) uncontrolled major seizure disorder , significant pulmonary disorder ( eg , interstitial pneumonitis , pulmonary hypertension ) , psychiatric disorder would interfere subject safety inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Neratinib</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Combination</keyword>
	<keyword>Solid Tumor</keyword>
</DOC>